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ABSTRACT 
 
The proton-activated G protein-coupled receptor GPR4 is expressed in many tissues 
including white adipose tissue. GPR4 is activated by extracellular protons in the 
physiological pH range (i.e. pH 7.7 - 6.8) and is coupled to the production of cAMP. 
Here we show that mice lacking GPR4 have an improved intraperitoneal glucose 
tolerance test and increased insulin sensitivity. Insulin levels were comparable but 
leptin levels were increased in GPR4 KO mice. Gpr4-/- showed altered expression of 
PPARα, IL-6, IL-10, TNFα, and TGF-1β in skeletal muscle, white adipose tissue, and 
liver. High fat diet abolished the differences in glucose tolerance and insulin 
sensitivity between Gpr4+/+ and Gpr4-/- mice. In contrast, in aged mice (12 months 
old), the positive effect of GPR4 deficiency on glucose tolerance and insulin 
sensitivity was maintained. Liver and adipose tissue showed no major differences in 
the mRNA expression of pro- and anti-inflammatory factors between aged mice of 
both genotypes. Thus, GPR4 deficiency improves glucose tolerance and insulin 
sensitivity. The effect may involve an altered balance between pro- and anti-
inflammatory factors in insulin target tissues. 
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INTRODUCTION 
 
 Insulin is a major regulator of systemic glucose homeostasis by stimulating 
glucose uptake and utilization by insulin-sensitive tissues such as liver, skeletal 
muscle, and adipose tissue as well as by regulating gluconeogenesis and 
glycogenolysis. Insulin resistance and type II diabetes can develop or are further 
promoted by pro-inflammatory cytokines, adipokines, or oxidative stress associated 
with conditions such as obesity or ageing [1-3]. Metabolic acidosis, as found in 
patients with chronic kidney disease, can further contribute to the development or 
maintenance of insulin resistance [4-7]. Similarly, lower blood bicarbonate levels are 
associated with insulin resistance and a higher risk to develop type 2 diabetes [8-9]. 
The mechanisms by which acidosis affects insulin sensitivity and contributes to the 
development of type 2 diabetes have not been elucidated to date. 
 In 2003 the G protein-coupled receptors OGR1 (Ovarian cancer G protein-
coupled receptor 1, GPCR68), GPR4, and TDAG8 (T-cell death associated gene 8, 
GPCR65) were recognized to be activated by extracellular protons [10-11]. These 
receptors had been initially described as receptors activated by 
sphingosylphosphorylcholine (SPC), lysophosphatidylcholine (LPC) and modulated 
by psychosine [11]. However, these publications were subsequently retracted [12-
14]. OGR1 and GPR4 are widely expressed on mRNA level in most organs, whereas 
the expression of TDAG8 appears to be restricted to few organs such as immune 
cells and bone. All three receptors are activated by extracellular protons in the 
physiological range for most extracellular fluids, e.g. very low activity for pH more 
alkaline than pH 7.8 and full activity around pH 6.8 [10-11, 15]. GPR4 and TDAG8 
are coupled to the production of cAMP whereas OGR1 is predominantly linked to 
phospholipase C activity, intracellular calcium rises, and protein kinase C stimulation 
[10-11, 15-17]. 
 The physiological function of these receptors is not fully understood to date. 
Mice lacking Ogr1 show impaired insulin secretion by pancreatic Beta cells but have 
normal glucose tolerance [18]. Also GPR4 deficient mice have been generated and 
described to suffer from a form of renal acidosis [19]. GPR4 and TDAG8 have been 
linked to the regulation of inflammatory cytokines and factors and chemotactic 
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migration of inflammatory cells [20-25]. Therefore, we were interested to test if GPR4 
modulates glucose homeostasis and if this effect would be associated with changes 
in the profile of pro-and anti-inflammatory factors in insulin target organs. 
 Here we demonstrate that GPR4 deficient mice have improved glucose 
tolerance due to increased insulin sensitivity. This phenotype is maintained in aged 
mice but not in mice with diet induced obesity and is associated with differential 
regulation of several pro- and anti-inflammatory factors in muscle, liver, and white 
adipose tissue.   
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METHODS 
 
Animals 
 All experiments were performed with wild-type (Gpr4+/+) and Gpr4 deficient 
(Gpr4-/-) mice bred in a pure Balb/c background. The generation, breeding and 
genotyping of Gpr4 KO mice have been described previously [26].  
Mice were maintained on a normal chow diet (4.5% fat, KLIBA NAFAG) if not 
stated otherwise. Some animals were fed a high fat diet (45% fat, Research Diets) 
beginning at 12 weeks of age. In each experiment, age-matched wild-type littermate 
mice were used as controls. 
All experiments were performed according to the Swiss Animal Welfare laws 
and approved by the local veterinary authority (Veterinäramt Zürich). 
 
 
mRNA extraction and semi-quantitative RT-PCR 
 Tissues were harvested and rapidly frozen in liquid nitrogen. Snap-frozen 
tissues were homogenized in RLT-Buffer (Qiagen, Basel, Switzerland) supplemented 
with ß-mercaptoethanol to a final concentration of 1%. Total RNA was extracted from 
200 µl aliquots of each homogenized sample using the RNeasy Mini Kit (Qiagen, 
Basel, Switzerland) according to the manufacturer’s instructions. Quality and 
concentration of the isolated RNA preparations were analyzed on a ND-1000 
spectrophotometer (NanoDrop Technologies). Total RNA samples were stored at -
80°C. Each RNA sample was diluted to 100 ng/µl and 3 µl used as a template for 
reverse transcription using the TaqMan Reverse Transcription Kit (Applied 
Biosystems, Forster City, CA, USA). For reverse transcription, 300 ng of RNA 
template were diluted in a 40-µl reaction mix that contained (final concentrations) RT 
buffer (1x), MgCl2 (5.5 mM), random hexamers (2.5 µM), RNase inhibitor (0.4 U/µl), 
the multiscribe reverse transcriptase enzyme (1.25 U/µl), dNTP mix (500 µM each), 
and RNase-free water. 
Semi-quantitative real-time qRT-PCR was performed on the ABI PRISM 7700 
Sequence Detection System (Applied Biosystems, Carlsbad, California). Primers for 
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all genes of interest were designed using Primer Express software from Applied 
Biosystems primers (see table 1). Primers were chosen to result in amplicons no 
longer than 150 bp spanning intron-exon boundaries to exclude genomic DNA 
contamination [28]. The specificity of all primers was first tested on mRNA derived 
from liver and white adipose tissue and always resulted in a single product of the 
expected size (data not shown). Probes were labelled with the reporter dye FAM at 
the 5’ end and the quencher dye TAMRA at the 3’ end (Microsynth, Balgach, 
Switzerland). Real-Time PCR reactions were performed using TaqMan Universal 
PCR Master Mix (Applied Biosystems). Briefly, 3.5 µl cDNA, 1 µl of each primer (25 
µM), 0.5 µl labelled probe (5 µM), 6.5 µl RNAse free water, 12.5 µl TaqMan Universal 
PCR Master Mix reached 25 µl of final reaction volume. Reaction conditions were: 
denaturation at 95oC for 10 minutes followed by 40 cycles of denaturation at 95oC for 
15 seconds and annealing/elongation at 60oC for 60 seconds with auto ramp time. All 
reactions were run in duplicate. For analysing the data, the threshold was set to 0.06 
as this value had been determined to be in the linear range of the amplification 
curves for all mRNAs in all experimental runs. The expression of gene of interest was 
calculated in relation to GAPDH or hypoxanthine guanine phosphoribosyl transferase 
(HPRT) as indicated. Relative expression ratios were calculated as R=2(Ct(HPRT)-Ct(test 
gene), where Ct represents the cycle number at the threshold 0.06. 
 
Glucose tolerance and insulin sensitivity tests 
 Mice were fasted overnight (from 6 p.m. to 8.a.m. next day) with free access to 
water. Body weight and blood glucose were measured, and animals injected with 
either glucose (2 g/Kg body weight) or insulin (0.75 IU/g BW) i.p. For measuring 
glucose tolerance, glucose measurements were repeated after 30, 60, 120, and 150 
min.. To determine insulin sensitivity, glucose measurements were repeated 15, 30, 
45, and 60 min after insulin injection. After the last glucose measurement, mice 
received a bolus of glucose to facilitate recovery. Blood for glucose measurements 
was obtained by puncturing the tail vein, and glucose levels were measured using 
Accu-Chek Aviva (Roche Diagnostics, Basel).  
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Measurements of insulin and leptin 
Plasma samples from 5 WT and 5 KO mice were prepared, immediately frozen and 
shipped to Rules Based Medicine (http://www.myriadrbm.com/products-services/the-
rbm-approach/) for measurement of analytes. 
 
Statistics 
All data were tested for statistical significance using the unpaired t-test and p< 0.05 
was considered as statistically significant.  
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RESULTS 
Expression of GPR4 in white adipose tissue 
GPR4 is widely expressed in mouse tissues as indicated by detection of GPR4 
mRNA using semi-quantitative RT-PCR (Figure 1). Among the tissues with high 
levels of GPR4 mRNA abundance are spleen, lung, and white adipose tissue.  
 
Absence of GPR4 increases insulin sensitivity 
Blood glucose levels were measured in the morning (9 a.m.) in 10 weeks-old 
male animals with free access to water and food overnight. Wild-type mice had blood 
glucose levels significantly higher than their Gpr4-/- littermates (218.2 ± 14.1 mg/dl vs. 
162.9 ± 13.6 mg/dl, p < 0.05, n = 5 Gpr4+/+ and 7 Gpr4-/-) suggesting that GPR4 may 
modulate glucose homeostasis (Figure 2A). Metabolic cage experiments had 
indicated similar rates of food intake (0.14 g/g BW/24 hrs for Gpr4+/+ and 0.14 g/g 
BW/24 hrs for Gpr4-/-, respectively, n = 6 per group). In order to directly test glucose 
tolerance, male mice were fasted overnight (with free access to water) and injected 
intraperitoneally the next morning with glucose (2 g/ Kg BW) and blood glucose was 
monitored for 150 min after injection. Gpr4-/- had lower initial blood glucose levels, 
however, after glucose injection Gpr4-/- showed increased blood glucose levels to 
similar values as Gpr4+/+ mice but returned faster to baseline values than their wild-
type littermates (Figure 2B, n = 10 Gpr4+/+ and n = 9 Gpr4-/-). Female mice were also 
tested and showed a similarly improved intraperitoneal glucose tolerance test (data 
not shown). Next we tested the effect of injecting insulin (0.75 IU/g BW) into male 
mice after overnight fasting. Fasting glucose levels were lower in Gpr4-/- but this 
difference did not reach significance in this particular set of experiments. Insulin 
caused a faster and stronger fall in blood glucose levels in Gpr4-/- than in Gpr4+/+ 
mice demonstrating increased insulin sensitivity in the absence of GPR4 (Figure 2C, 
n=8 Gpr4+/+ and 9 Gpr4-/-). Again, female mice showed similar results (data not 
shown). Bodyweight was similar between wild-type and KO mice if corrected for 
gender. We also dissected mice and measured weights of organs, total fat, and 
skeleton plus muscle and did not find any difference between genotypes (6 animals 
each) (data not shown). 
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 Next, we measured plasma leptin and insulin levels in mice fed ad libitum and 
found no difference for insulin (Gpr4+/+ 0.85 ± 0.09 µIU vs. Gpr4-/- 1.09 ± 0.14 µIU, n 
= 5 each) but higher levels of leptin in GPR4 KO mice (Gpr4+/+ 0.42 ± 0.02 ng/ml vs. 
Gpr4-/- 0.62 ± 0.07 ng/ml, n = 5 each).   
 
Altered expression of pro- and anti-inflammatory factors in insulin target 
tissues 
 The major insulin-sensitive tissues are liver, skeletal muscle and white adipose 
tissue and insulin sensitivity and glucose uptake are modulated by a variety of factors 
including pro- and anti-inflammatory factors. We examined therefore the expression 
of major modulators of insulin sensitivity in these tissues. In skeletal muscle lower 
expression of IL-6 and PPARα were found whereas TNFα, IL-10, IL-1β, CD-11c, and 
TGF-1 β were not altered (Figure 4A). In liver, PPARα was reduced and IL-10 
expression increased. All other factors remained unchanged (Figure 4B). The 
strongest changes were found in white adipose tissue with TNFα and TGF-1β being 
elevated and IL-6 and PPARα being reduced (Figure 4C). Taken together, these data 
suggest that absence of GPR4 alters the balance between pro- anti-inflammatory 
factors in insulin target tissues. 
 
High fat diet and ageing modulate the impact of GPR4 on glucose metabolism 
Obesity due to high fat diet or ageing negatively impacts on glucose 
metabolism and insulin sensitivity [1-3]. Thus, we tested if obesity and ageing 
modulated the positive effect of GPR4 deletion on insulin sensitivity.  
In a first series, we fed 12 week old Gpr4+/+ and Gpr4-/- mice for 16 weeks with 
a high fat diet (45% fat). Body weight gain was identical in both groups (data not 
shown). We also monitored intraperitoneal glucose tolerance (IPGTT) before the start 
of the diet (12 weeks old mice) and at the end of the diet (28 weeks old mice). As 
expected, in 12 weeks old mice, IPGTT was improved and insulin sensitivity 
increased in Gpr4-/- mice (Figure 5A,C). After 16 weeks of high fat diet Gpr4+/+ 
showed in the IPGTT elevated glucose levels as compared to the IPGTT before the 
start of the diet consistent with reduced glucose tolerance (Figure 5B). In Gpr4-/- the 
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increase in blood glucose levels was even more pronounced. Insulin sensitivity was 
similar in Gpr4+/+ and Gpr4-/- (Figure 5D). Consistently, we also found higher glucose 
levels in Gpr4-/- fed ad libitum whereas fasting blood glucose levels were similar in 
both genotypes (Figure 5E). 
Therefore, we examined expression of pro- and anti-inflammatory factors in 
white adipose tissue and liver collected from mice either fed or fasted overnight. In 
mice fed ad libitum, elevated expression of TNFα and TGF-1β was found in white 
adipose tissue. In the same tissue, higher levels of IL-6 and lower levels of PPARα 
mRNA was found in fasting Gpr4-/- mice (Figure 6A).  In liver tissue, only IL-10 mRNA 
was increased in fed Gpr4-/- mice. In fasting animals, IL-6 and PPARα were reduced 
in Gpr4-/- liver whereas IL-10 and CD-11c were highly elevated (Figure 6B). 
 In a second series of animals, we allowed mice to age to 12 months (n = 9 per 
genotype) and assessed IPGTT and insulin sensitivity. In contrast to mice fed a high 
fat diet, Gpr4-/- retained an improved IPGTT and greater insulin sensitivity than wild-
type littermates (Figure 7). Measurement of mRNAs of pro- and anti-inflammatory 
factors in white adipose tissue and liver did not detect any significant differences 
between Gpr4+/+ and Gpr4-/- mice, respectively (Figures 8A and 8B).  
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DISCUSSION 
 
 We present three major findings in this study: i) GPR4 modulates glucose 
tolerance by increasing the sensitivity to insulin, ii) the effect of GPR4 is lost in obese 
animals but not in aged animals, and iii) the absence of GPR4 alters the expression 
profile of pro- and anti-inflammatory factors in insulin target tissues. 
 In the absence of GPR4, mice had lower fasting and fed glucose levels. Fed 
mice had also lower insulin and higher leptin levels. The intraperitoneal glucose 
tolerance test confirmed the improved glucose tolerance in Gpr4-/- and the insulin 
sensitivity test demonstrated that the improved glucose tolerance is most likely due to 
enhanced insulin sensitivity. The lower insulin levels in fed mice are consistent with 
this notion. This is in contrast to mice lacking another member of the pH-sensitive G 
protein-coupled receptors, OGR1 [18]. OGR1 as well as GPR4 and TDAG8 are 
expressed in pancreatic β-cells and OGR1 modulates their insulin secretion in 
response to glucose or KCl induced depolarization coupled to a pathway involving 
intracellular Ca2+ rises [18]. The role of GPR4 in β-cells requires further experiments 
but our data suggest that the improved glucose tolerance is at least in part explained 
by higher insulin sensitivity of insulin target organs. In mice lacking TDAG8 we did 
not find any change in glucose tolerance suggesting that TDAG8 might be involved in 
other functions in these cells (data not shown). 
 We tested next if the improved glucose tolerance and insulin sensitivity in 
Gpr4 KO mice was maintained if mice were challenged with a high fat diet for 16 
weeks or if aged, conditions associated with increased insulin resistance. High fat 
diet caused a similar increase in body weight in both groups, abolished the difference 
in insulin sensitivity, and caused an even higher glucose intolerance in Gpr4-/- mice. 
In contrast, in aged mice the higher insulin sensitivity and improved glucose tolerance 
were maintained in mice lacking GPR4. Thus, absence of GPR4 does not per se 
improve insulin sensitivity but the effect is modulated by other factors. 
 
 Deletion of GPR4 was associated with profound changes in the mRNA 
expression profile of various pro- and anti-inflammatory factors in insulin target 
organs that have been shown to affect glucose tolerance and insulin sensitivity. We 
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tested the pro-inflammatory molecules TNFα, Cd11c, a marker for pro-inflammatory 
M1 macrophages, IL-6, and IL-1β which cause reduced glucose tolerance and insulin 
resistance by acting on pancreatic β-cells as well as on the pathways mediating 
cellular insulin effects such as IRS-1 phosphorylation [29-33]. In young GPR4 
deficient mice, reduced levels of IL-6 were found in muscle and white adipose tissue, 
whereas TNFα was up-regulated in white adipose tissue. When GPR4 KO mice were 
challenged with a high fat diet or aged, reduced IL-6 levels persisted in liver but were 
elevated in white adipose tissue from acutely fed GPR4 KO mice. TNFa was reduced 
in white adipose tissue of fasted GPR4 KO mice.  
 We also assessed the mRNA expression of anti-inflammatory markers in the 
same tissues, namely PPARα, IL-10 and TGF1β which have been shown to improve 
glucose tolerance and/or insulin sensitivity [1, 32, 34]. Surprisingly, in GPR4 KO mice 
PPARα was down-regulated in most conditions in liver, white adipose tissue and 
skeletal muscle. In contrast, profound increases were observed for IL-10 in liver from 
young mice as well as from mice fed a high fat diet. TGF1β showed only weak 
regulation in abdominal white fat tissue being slightly upregulated in young Gpr4-/- 
mice which would support increased insulin sensitivity in this tissue. However, in 
aged mice maintaining improved insulin sensitivity, no evidence for TGF1β regulation 
was detected suggesting that increased insulin sensitivity may occur independent 
from TGF1β regulation. 
 Despite strong regulation of pro- and anti-inflammatory markers in GPR4 KO 
mice, it remains unclear if and how these changes caused improved glucose 
tolerance and insulin sensitivity. Factors involved in modulating glucose tolerance 
and insulin sensitivity showed patterns of regulation that did not clearly correlate with 
improved glucose tolerance of young or aged GPR4 KO. In the case of the high fat 
fed mice, GPR4 KO showed an even reduced glucose tolerance, however, IL-10 
associated with improved glucose tolerance was up-regulated. In aged mice, no 
significant regulation of any of the factors tested was found despite highly improved 
glucose tolerance in GPR4 deficient mice. Thus, either other factors not identified to 
date mediate the effects of GPR4 deletion on insulin sensitivity or the balance 
between the pro- and anti-inflammatory factors is more strongly influenced by single 
factors than obvious from our data.   
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 Related to this problem is the question, in which organ and cell type(s) and 
how GPR4 modulates insulin sensitivity. GPR4 mRNA was detected in several major 
organs involved in insulin-sensitive glucose metabolism, most prominently in white 
adipose tissue. However, this tissue consists of several cell types including 
adipocytes, immune cells, and vascular cells. The localization of GPR4 on cellular 
level has been hampered by the fact that no specific antibodies have been available 
up to date and that alternative methods such as in-situ hybridization failed to detect 
GPR4 mRNA reliably. Recent reports, however, indicate that GPR4 is highly 
expressed in endothelial cells [26, 35] and that endothelial cells play a critical role in 
modulating insulin sensitivity of adipose tissue [36].  
 GPR4 deficient mice are mildly acidotic [19] and acidosis has been associated 
with increased insulin resistance and reduced glucose tolerance in CKD patients [4-
7]. Whether GPR4 participates in this dysregulation being more activated in acidosis 
and thereby reducing insulin sensitivity remains to be examined. 
 In summary, we demonstrate that the proton-activated G protein-coupled 
receptor GPR4 modulates glucose tolerance and insulin sensitivity in mice and this 
effect is maintained in aged mice but not in animals fed a high fat diet.  
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FIGURE LEGENDS 
Table 1: List of primers and probes for semi-quantitative real-time RT-PCR 
 
Figure 1 
Expression of GPR4 mRNA in various mouse tissues.  
Semi-quantitative real-time RT-PCR was performed on various mouse tissues (n = 5 
male mice) and GPR4 mRNA detected in most organs. Highest relative mRNA levels 
were seen in abdominal white adipose tissue. 
 
Figure 2 
Glucose homeostasis in 10 weeks old Gpr4+/+ and Gpr4-/- mice 
(A) Blood glucose levels in male mice eating ad libitum (n = 5 Gpr4+/+ and 7 Gpr4-/- 
mice). (B) Intraperitoneal glucose tolerance test in overnight fasted male Gpr4+/+ (n = 
10) and Gpr4-/- (n =9) mice. (C) Insulin sensitivity test in overnight fasted male 
Gpr4+/+ (n = 8) and Gpr4-/- mice (n = 9). Data are shown as mean ± SEM, * p ≤ 0.05, 
** p ≤ 0.01. 
 
Figure 3 
Leptin and insulin levels 
Blood insulin and leptin levels were measured in Gpr4+/+ (n = 5) and Gpr4-/- (n = 5) 
mice. Data are shown as mean ± SEM, * p ≤ 0.05. 
 
Figure 4 
mRNA expression of pro- and anti-inflammatory factors in young mice  
Semi-quantitative RT-PCR was performed on tissues from young (10 weeks old) 
Gpr4+/+ and Gpr4-/- mice and mRNA expression of pro- and anti-inflammatory factors 
assessed. (A) mRNA expression in skeletal muscle (upper hind leg), (B) in liver, and 
15 
 
(C) in abdominal white adipose tissue. n = 5 Gpr4+/+ and n = 5 Gpr4-/-, * p ≤ 0.05, ** p 
≤ 0.01. 
 
Figure 5 
High fat diet abolishes improved glucose tolerance and higher insulin 
sensitivity in Gpr4-/- mice 
Gpr4+/+ and Gpr4-/- received high fat diet for 16 weeks. (A) Intraperitoneal glucose 
tolerance test (IPGTT) in Gpr4+/+ and Gpr4-/- mice at the age of 12 weeks before the 
start of the high fat diet. (B) Insulin tolerance test in Gpr4+/+ and Gpr4-/- mice at the 
age of 12 weeks before the start of the high fat diet. (C) Intraperitoneal glucose 
tolerance test (IPGTT) in Gpr4+/+ and Gpr4-/- mice at the age of 28 weeks after the 
high fat diet. (D) Insulin tolerance test in Gpr4+/+ and Gpr4-/- mice at the same age. 
(E) Blood glucose levels in fasted and fed Gpr4+/+ and Gpr4-/- mice at the age of 28 
weeks. n = 18 Gpr4+/+ and n = 10 Gpr4-/-. Data are shown as mean ± SEM, * p ≤ 
0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
 
Figure 6 
mRNA expression of pro- and anti-inflammatory factors in mice after 16 weeks 
of high fat diet  
Semi-quantitative RT-PCR was performed on tissues from Gpr4+/+ and Gpr4-/- mice 
receiving a high fat diet for 16 weeks and mRNA expression of pro- and anti-
inflammatory factors assessed. (A) mRNA expression in abdominal white adipose 
and (B) in liver. n = 6 Gpr4+/+ and n = 7 Gpr4-/-, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
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Figure 7 
Maintained improved glucose tolerance and higher insulin sensitivity in aged 
Gpr4-/- mice 
Gpr4+/+ and Gpr4-/- at the age of 12 months were tested by (A) an intraperitoneal 
glucose tolerance test (IPGTT) with (B) an insulin tolerance test. Data are shown as 
mean ± SEM, ** p ≤ 0.01, *** p ≤ 0.001. 
 
Figure 8 
mRNA expression of pro- and anti-inflammatory factors in 12 month old mice 
Semi-quantitative RT-PCR was performed on tissues from Gpr4+/+ and Gpr4-/- mice 
aged 12 months and mRNA expression of pro- and anti-inflammatory factors 
assessed. (A) mRNA expression in abdominal white adipose and (B) in liver. n = 6 
Gpr4+/+ and n = 6 Gpr4-/-, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
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Table 1: Primers and probes used for real-time PCR 
 
Gene Primers Probe Acc. No. 
CD-11c S: 5'-TAC TGA GTT CAT CAT TCA AGC AGA G (456-
480) 
 
 
A: 5'-GGA ACA CGA TGT CTT GGT CTT GCT (516-
539) 
5'-ACT TCC CAA CTG CAC AGC AGG AGT GTC 
(486-512) 
NM_021334 
IL-10 S: 5'-CCT TAA TGC AGG ACT TTA AGG GTT A (273-
297) 
 
 
A: 5'-GGG CAT CAC TTC TAC CAG GTA AAA (332-
355) 
5'-TGG GTT GCC AAG CCT TAT CGG AAA TG (300-
325) 
NM_010548 
IL-1b S: 5'-AAT GGA CAG AAT ATC AAC CAA CAA G (532-
556) 
 
 
A: 5'-CTG CAG GGT GGG TGT GCC GTC T (660-681) 
5'-TGA GCT TTG TAC AAG GAG AAC CAA GCA AC 
(569-597) 
NM_008361 
IL-6 S: 5'-AAC AAT CTG AAA CTT CCA GAG ATA C (305-
329) 
 
 
A: 5'-GCT ATG GTA CTC CAG AAG ACC AGA (392-
415) 
5'-TGA TGG ATG CTA CCA AAC TGG ATA TAA TC 
(337-365) 
NM_031168 
PPAR-a S: 5'-GAT TCA GAA GAA GAA CCG GAA CA (877-
899) 
 
 
A: 5'-TGC TTT TTC AGA TCT TGG CAT TC (969-991) 
5'-ATG TCA CAC AAT GCA ATT CGC TTT GG (941-
966) 
NM_011144 
  
TGF-1b S: 5'-AGA GGT CAC CCG CGT GCT A (632-650) 
 
 
A: 5'-GCT TCC CGA ATG TCT GAC GTA (722-742) 
5'-ACC GCA ACA ACG CCA TCT ATG AGA AAA CC 
(658-686) 
NM_011577 
TNFa S: 5'-CAG ACC CTC ACA CTC AGA TCA TCT (393-
416) 
 
 
A: 5'-CCT CCA CTT GGT GGT TTG CT (455-474) 
5'-ATT CGA GTG ACA AGC CTG TAG CCC ACG T 
(424-451) 
NM_013693 
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